---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-25-000526"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:33:51.029369+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical reports FY2024 net loss $23.5M; obesity implant trials on track for mid-2025 data

## Summary
- FY2024 net loss $23.5M vs $25.7M YoY; cash $19.7M at Dec 31, 2024.
- LIBERATE-1 (NPM-115 exenatide) fully enrolled; top-line data expected mid-2025.
- NPM-139 (semaglutide) preclinical data positive, once-yearly dosing potential.
- Closed $8.25M equity financing on March 27, 2025 to fund into Q2 2026.
- Plans to spin off Cortigent subsidiary as independent public company.

## SEC filing metadata
- accession: 0001753926-25-000526
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392625000526/0001753926-25-000526-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392625000526/vani-20250331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-25-000526
- JSON: https://secwatch.observer/filing/0001753926-25-000526.json
- Plain text: https://secwatch.observer/filing/0001753926-25-000526.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.